About Management of Cough in Patients with Community-acquired Pneumonia: the Results of MUCASTAT PLUS Trial

##plugins.themes.bootstrap3.article.main##

І. Г. Березняков
М. М. Лебединська
В. І. Березняков
О. В. Дорошенко
В. Й. Пожар

Abstract

The objective: to study an effectiveness and tolerability of free prescription by physicians of erdostein and ambroxol for management of cough in hospitalized patients with non-severe community-acquired pneumonia on the background of standard antibacterial treatment after completion of MUCASTAT trial.

Materials and methods. 245 patients (110 men and 135 women) aged 21–82 years were included in an open prospective non-randomized study. All the patients received standard antibacterial treatment for 7–10 days and mucoactive drugs of erdosteine (Mucitus) or ambroxol in standard dosages for no less then 6 days. CAP-Sym-12 and Scale of Estimation of CAP (SECAP) questionnaires were used to estimate pneumonia-related symptoms.

Results. In 2–3 days from the beginning of therapy the patients from erdosteine group began to estimate their well-being (condition) and cough intensity (according to CAP-Sym-12 questionnaire) better, than patients from ambroxol group. In subsequent observation periods (in 7±1 and 12±2 days from the beginning of treatment) superiority of erdosteine was documented by objective (lesser quantity of patients suffering from cough and sputum expectoration) and subjective methods (CAP-Sym-12 and SECAP questionnaires).

Conclusion. An effectiveness, good tolerability and superiority of erdosteine over ambroxol for management of cough and sputum expectoration in hospitalized patients with community acquired pneumonia on the background of standard antibacterial treatment were confirmed in MUCASTAT PLUS study.

##plugins.themes.bootstrap3.article.details##

How to Cite
Березняков, І. Г., Лебединська, М. М., Березняков, В. І., Дорошенко, О. В., & Пожар, В. Й. (2019). About Management of Cough in Patients with Community-acquired Pneumonia: the Results of MUCASTAT PLUS Trial. Family Medicine, (5-6), 64–69. https://doi.org/10.30841/2307-5112.5-6.2019.193626
Section
For practicing physicians
Author Biographies

І. Г. Березняков, Kharkiv Medical Academy of Postgraduate Education

Ihor G. Bereznyakov,

Head of Department of Therapy

М. М. Лебединська, Kharkiv Medical Academy of Postgraduate Education

Maryna M. Lebedynska,

Department of Therapy

В. І. Березняков, Kharkiv Medical Academy of Postgraduate Education

Vladyslav I. Bereznyakov,

Department of Therapy

О. В. Дорошенко, Kharkiv Medical Academy of Postgraduate Education

Oksana V. Doroshenko,

Department of Therapy

В. Й. Пожар, Kharkiv Medical Academy of Postgraduate Education

Vira Yo. Pozhar,

Department of Therapy

References

Guidelines for the management of adult lower respiratory tract infections / M. Woodhead, F. Blasi, S. Ewig [et al.] // Clin. Microbiol. Infect. – 2011. – Vol. 17, Suppl. 6. – P. E1–E59.

Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America / J.P. Metlay, G.W. Waterer, A.C. Long [et al.] // Am. J. Respir. Crit. Care Med. – 2019. – Vol. 200. – No. 7. – P. e45–e67.

National Institute for Health and Care Excellence. Pneumonia (communityacquired): antimicrobial prescribing. 2019. Доступно по адресу: www.nice.org.uk/guidance/ng138

National Institute for Health and Care Excellence. Pneumonia (including community-acquired pneumonia). 2014. Доступно по адресу: www.nice.org.uk/guidance/cg191

Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults / C.C. Chang, A.C. Cheng, A.B. Chang // Cochrane Database Syst. Rev. – 2012. – Issue 2. – Art. No.: CD006088.

Эффективность эрдостеина для лечения кашля у больных внебольничными пневмониями: результаты исследования МУКАСТАТ / И.Г. Березняков, М.Н. Лебединская, В.И. Березняков, И.Д. Ломино // Сімейна медицина. – 2017. – № 4 (72). – С. 100–104.

Махаринська О.С. Застосування та валідизація короткого опитувальника для хворих на негоспітальну пневмонію в Україні / Махаринська О.С., Лебединська М.М., Березняков І.Г. // Болезни и антибиотики. – 2012. – № 1. – С. 51–58.

Березняков І.Г. Особливості перебігу нетяжкої негоспітальної пневмонії у осіб із супутньою хронічною серцевою недостатністю / І.Г. Березняков, М.М. Лебединська // Болезни и антибиотики. – 2013. – № 1. – С. 36–48.

Корж А.Н. Эффективность ступенчатой терапии у больных с внебольничными пневмониями с сопутствующей хронической сердечной недостаточностью / А.Н. Корж, В.И. Березняков // Болезни и антибиотики. – 2013. – № 1. – С. 13–22.

Adult outpatients with acute cough due to suspected pneumonia or influenza. CHEST Guideline and Expert Panel Report / A.T. Hill, P.M. Gold, A.A. El Solh [et al.] // Chest. – 2019. – Vol. 155. – No. 1. – P. 155–167.

Clinical effectiveness of a combination of bromhexine and amoxicillin in lower respiratory tract infection. A randomized controlled trial / C.C. Jr. Roa, R.B. Dantes // Fortschritte der Arzneimittelforschung. – 1995. – Vol. 45, № 3. – P. 267–72.

Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease // Expert. Rev. Resp. Med. – 2007. – Vol. 1, No. 3. – P. 307–316.

Cazzola M. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data / M. Cazzola, I. Floriani, C.P. Page // Pulmon. Pharmacol. Ther. – 2010. – V. 23. – No. 2. – P. 135–144.

Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study / R.W. Dal Negro, J.A. Wedzicha, M. Iversen M [et al.] // Eur. Respir. J. – 2017. – Vol. 50. – P. 1700711.

Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine / P. Rogliani, M.G. Matera, C. Page [et al.] // Respir. Research. – 2019. – Vol. 20. – P. 104.